-
Most Recent
Healthcare Stocks
Healthcare encompasses a wide range of organized services to prevent, treat, and diagnose medical needs and mental illnesses. The $336 billion market is expected to grow at a compound annual growth rate of 8% until 2030, demonstrating the necessity of adequate healthcare. Healthcare companies, ranging from retailer CVS to insurance giant UnitedHealth, provide these services to a massive customer base.
7 Recession-Resistant Stocks to Hold Onto for Dear Life in 2024
These seven recession-resistant stocks offer stability and potential growth even in challenging economic conditions.
7 Dependable Dividend Stocks for Long-Term Income
Explore the best dividend stocks for long-term income excelling in the healthcare, retail, tobacco and home improvement markets.
3 Pharmaceutical Stocks That Can Surge Higher Even if The Markets Correct
These are the pharmaceutical stocks to buy as they represent undervalued companies with a deep clinical pipeline that will support growth.
Other industries you might be interested in
Recent Healthcare Stocks Articles
Pages of Purple Prose and a Healthcare Stock Pick
The Supreme Court ruling will have its effect as time goes on for a variety of industries, but for now one hospital stock, WellPoint, looks like a buy
Court Speaks, Markets Listen — Thursday’s IP Market Recap
The Supreme Court ruling in favor of Obama's Affordable Care Act hit markets initially, but the indices managed to cut most losses by the end of the day.
Winners and Losers From the High Court Obamacare Ruling
After the volatility dies down, here's the likely lay of the land now that this historic decision is made. At least one group seems to be a sure winner.
What’s the Real Impact of Generic Drugs?
The danger of patent expirations for big pharma isn't new, but the amount of market share those brands are losing to generics as a result are not pretty.
A Ruling That’s Good for Health Care Stocks
A $2.7 trillion industry representing 18% of the economy now knows where it's headed. Losing the individual mandate would have been a worst-case scenario for it.
How Non-Beach Bums Should Play the Obamacare Decision
Light volume indicates most investors are playing it safe and heading for the beach. Here's what non-beach bums should know.
3 Reasons to Flee Walgreen
The market is worried that Walgreen is still struggling to fill the right prescription at the right time. Here are three signs that spell trouble for WAG shares.
4 Reasons to Buy UnitedHealth, 2 Ways to Play
Let’s take a look at the things that should drive UNH higher over the coming year.
5 of Pharma’s Most Disastrous Drug Approvals
These five exciting drug approvals now serve as warning stories about the potential pitfalls for investors trying to time a pharma stock buy.
Wait on Arena’s Weight-Loss Drug
The FDA is all set to rule on Arena Pharmaceuticals' weight loss drug lorcaserin, and things look good, but its approval might already be priced in.
The Obamacare Ruling: 5 Investing Scenarios
The Supreme Court's looming decision will surely create winners and losers among health care stocks. Here's an investor's guide to the possible outcomes.
Don’t Buy Pharma Stocks — Buy THESE Pharma Stocks
If your sliver of the pharma pie is too small, it's easy to fall into the "any old pharma stock will do" trap. Keep your eye on the prize with these must-own names.
Time to Take Profits at Cerner
Cerner has been in our portfolio for a fairly short time but has performed extremely well. Now is a good time to lock in profits.
Pfizer to Spin Off Its Animal Health Biz
Pfizer announced Thursday its plan to spin off its animal health business into a stand-alone company named Zoetis.
3 Stocks to Help Weather the Financial Storm
After weathering the May storm and surviving Europe's turmoil, these three picks are inexpensive at this point.
Myriad Genetics Is a Biotech Buy
Myriad Technologies offers tests used to predetermine cancers and other diseases to provide pretreatment or prevention. Myriad is a biotech buy.
Genetic Testing a Chance to Profit From Prevention
Genetic testing and the sequencing of the gene is now 12 years old, and opportunities to profit through wise stock picks abound at this point.
